

Karolinska Cell Therapy Center (KCC)

Information and science seminar on clinical applications of advanced therapy medicinal products (ATMPs)

Venue: Birkeaulan, Birke 2, F52, Huddinge hospital

Date: Nov 10 2017, 9-12 am

Preliminary program	
Time	Program
Part 1: Information about KCC and the priority board at KCC	
9.00	Welcome, background to KCC – Pontus Blomberg (Director of KCC), Nina Nelson Follin (Director of Quality and Patient Safety)
9.10	KCC and the Priority Board - Harald Blegen (Managing Director Cancer)
9.20	Pre-GMP at KI - Matti Sällberg (Head of LabMed)
9.30	Manufacturing ATMP – Jenny Enger (QA/QP, KCC/Vecura)
9.40	TBA (procurement of cell products) - Maria Matl (Head of Clinical Immunology/Transfusion medicine)
9.50	Clinical trials - Berit Larsson (Head of Support unit, Karolinska Trial Alliance)
10.00	Coffee and mingle
Part 2: Scientific seminar with presentations of clinical studies of ATMPs	
10.30	Natural Killer Cell-based immunotherapy for high-risk myeloid diseases - Andreas Björklund (Karolinska Universitetssjukhuset)
10.45	Boost Brittle Bones before Birth (BOOSTB4) - Cecilia Götherström (Karolinska Institutet)
11.00	CD19 targeting 3rd generation CAR T cells for refractory B cell malignancy - Magnus Essand (Uppsala Universitet)
11.15	Cell therapy of malignant melanoma at Karolinska University Hospital - Stina Wickström (Karolinska Universitetssjukhuset)
11.30	To pave a road, clinical development of CellProtect, an ATMP - Karin Mellström (CellProtect Nordic Pharmaceuticals AB)
11.45	Development of mesenchymal stromal cells as advanced therapy - Katarina Le Blanc (Karolinska Universitetssjukhuset)
12.00	Concluding Remark – Pontus Blomberg (KCC)

Sign up to KCC.karolinska@sl.se, latest Nov 7